Breast Cancer Screening Tests Market Forecasts to 2030 – Global Analysis By Test Type (Blood Tests, Imaging Test, Genetic Test, Biopsy, Tomosynthesis and Other Test Types), Gender, End User and By Geography

Breast Cancer Screening Tests Market Forecasts to 2030 – Global Analysis By Test Type (Blood Tests, Imaging Test, Genetic Test, Biopsy, Tomosynthesis and Other Test Types), Gender, End User and By Geography

According to Stratistics MRC, the Global Breast Cancer Screening Tests Market is accounted for $2.29 billion in 2024 and is expected to reach $4.01 billion by 2030 growing at a CAGR of 9.8% during the forecast period. Breast cancer screening tests are medical procedures used to detect early signs of breast cancer in individuals who show no symptoms. The primary screening methods include mammography, ultrasound, MRI, and 3D mammography (tomosynthesis). These tests aim to identify abnormal growths or changes in breast tissue, allowing for early diagnosis and treatment. Regular screening helps improve survival rates by detecting tumours at an earlier, more treatable stage, especially in individuals at higher risk for breast cancer.

According to the European Breast Cancer Coalition 2023, breast cancer was the most commonly diagnosed cancer in Europe in 2023, with around 380,000 new cases, primarily among women.

Market Dynamics:

Driver:

Increasing awareness of early detection

Growing awareness of early detection is essential to the market expansion for breast cancer screening tests. Demand for screening services has increased dramatically as more individuals realize how important it is to detect cancer in its early stages. Health organizations' campaigning, media attention, and educational efforts have highlighted the life-saving advantages of early identification. Participation in screening programs has increased as a result of this knowledge, particularly among high-risk groups. Numerous screening techniques, including mammography, MRI, and ultrasound, are being used by a wide range of demographics due to the fact that early identification through routine screening improves treatment results and survival rates.

Restraint:

Radiation exposure concerns

Concerns about radiation exposure present a major obstacle to the market for breast cancer screening technologies, especially when using low-dose X-rays in standard procedures like mammography. Even while the radiation used in mammograms is considered to be low and safe for the majority of women, prolonged exposure might cause health hazards, such as an elevated risk of cancer. Particularly for younger women or those with a family history of cancer, these worries may discourage some people from getting frequent checkups. Alternative, non-radiative screening techniques like MRI and ultrasound are now being investigated in an effort to lower these hazards and guarantee efficient early identification.

Opportunity:

Rising awareness of genetic risk factors

Growing awareness of genetic risks, especially those associated with mutations in the BRCA1 and BRCA2 genes, has led to an increase in the number of people choosing early screening and genetic testing. Women are encouraged to get regular screenings at a younger age because of this awareness, particularly those who have a family history of breast cancer. When paired with screening procedures like MRIs and mammograms, genetic counseling assists in identifying high-risk patients, facilitating early detection and proactive monitoring. The need for better screening techniques and genetic testing is increasing along with awareness.

Threat:

Shortage of skilled healthcare professionals

The lack of qualified medical personnel, especially radiologists and technicians, is a major obstacle in the market for breast cancer screening testing. It takes highly qualified specialists to accurately interpret screening data, such mammograms, and their absence can cause delays in diagnosis and decreased screening efficacy. The lack of trained staff restricts access to timely tests in many areas, particularly in rural or underprivileged areas, which has a detrimental effect on early detection initiatives. Healthcare systems are further burdened by this scarcity, underscoring the necessity of funding educational initiatives and the creation of AI-powered diagnostic technologies to assist medical practitioners.

Covid-19 Impact

The COVID-19 pandemic significantly disrupted the breast cancer screening tests market, as many healthcare facilities temporarily suspended routine screenings to prioritize COVID-19 care. This led to delays in early detection, potentially affecting patient outcomes. Additionally, lockdowns and fear of exposure to the virus discouraged individuals from seeking screening services. However, as healthcare systems adapt, there has been a gradual recovery with the implementation of safety measures, increased use of telemedicine, and a focus on resuming delayed screenings for early diagnosis.

The imaging test segment is expected to be the largest during the forecast period

The imaging test segment is estimated to be the largest, driven by advancements in diagnostic technologies, such as 3D mammography, MRI, and ultrasound. These imaging tests provide higher accuracy, early detection of tumours, and better differentiation between benign and malignant growths. Additionally, the increasing prevalence of breast cancer, along with rising awareness of early detection, fuels the adoption of imaging tests. Technological innovations, improved image resolution, and integration of artificial intelligence further enhance the effectiveness of imaging in breast cancer diagnosis.

The diagnostic laboratories segment is expected to have the highest CAGR during the forecast period

The diagnostic laboratories segment is anticipated to witness the highest CAGR during the forecast period, as they provide specialized diagnostic services using advanced technologies like mammography, ultrasound, and MRI. The increasing demand for accurate and early breast cancer detection fuels growth in diagnostic labs. Additionally, improved healthcare infrastructure and rising awareness of breast cancer prevention contribute to higher patient volumes. Laboratories' ability to offer timely and precise diagnostic results further enhances their importance in the early detection and treatment of breast cancer.

Region with largest share:

Asia Pacific is expected to have the largest market share during the forecast period due to growing healthcare awareness, increasing breast cancer prevalence, and rising disposable incomes. Rapid urbanization and improvements in healthcare infrastructure are making screening services more accessible. Government initiatives and screening programs in countries like Japan, China, and India are promoting early detection. Additionally, a rising focus on women’s health, coupled with advancements in diagnostic technologies, further boosts the adoption of breast cancer screening tests across the region.

Region with highest CAGR:

During the forecast period, the North America region is anticipated to register the highest CAGR, fueled by factors such as high healthcare standards, strong government support, and advanced medical technologies. The widespread availability of screening programs, including mammography and MRI, encourages early detection and preventive care. Rising awareness about breast cancer, coupled with increased health insurance coverage, promotes regular screenings. Additionally, the aging population, high disposable incomes, and access to cutting-edge diagnostic tools further contribute to the market’s growth in North America.

Key players in the market

Some of the key players profiled in the Breast Cancer Screening Tests Market include GE Healthcare, Hologic, Inc., Siemens Healthineers, Philips Healthcare, Canon Medical Systems Corporation, Koninklijke Philips N.V., Fujifilm Holdings Corporation, IQM Diagnostics, Medtronic PLC, 3M Health Care, Samsung Medison Co., Ltd., Carestream Health, Inc., Inovio Pharmaceuticals, Inc., Volpara Health Technologies, Medimaps Group, Dilon Technologies, Inc., LumaVision, and Aurora Imaging Technology, Inc.

Key Developments:

In March 2024, Philips strengthens strategic partnership with Sim&Cure to expand innovation in neurovascular therapy. Philips announced the expansion of its strategic partnership with Sim&Cure, a leading provider of advanced digital solutions for neurovascular therapy. The partnership between the two companies started 5 years ago.

In May 2024, Samsung Medison, a global medical equipment company and an affiliate of Samsung Electronics, announced it has signed an agreement to acquire 100% of the shares of Sonio SAS, a fetal ultrasound AI software company.

In March 2024, GE Healthcare Wipro, a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, today announced an investment of over INR8000 Crores in manufacturing output & local R&D over next 5 years.

Test Types Covered:
• Blood Tests
• Imaging Test
• Genetic Test
• Biopsy
• Tomosynthesis
• Other Test Types

Genders Covered:
• Male
• Female

End Users Covered:
• Diagnostic Laboratories
• Hospitals
• Specialty Clinics
• Cancer Institutes
• Research Laboratories
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements